证券代码：301363 证券简称：美好医疗 公告编号：2025-064 深圳市美好创亿医疗科技股份有限公司 关于召开2025年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）第二届董事会第 二十一次会议决定于2025年10月9日（星期四）15:00召开2025年第二次临时股东会 （以下简称"本次股东会"），本次股东会采取现场投票和网络投票相结合的方式 召开，现将有关事项提示如下： 一、召开会议的基本情况 1.股东会届次：2025年第二次临时股东会 2.股东会的召集人：公司董事会 3.会议召开的合法、合规性：本次会议召开符合有关法律、行政法规、部门规 章、规范性文件、深圳证券交易所业务规则和《公司章程》等的规定。 4.会议召开的日期、时间 （1）现场会议时间：2025年10月9日（星期四）15:00 （2）网络投票时间：2025年10月9日（星期四）。其中，通过深圳证券交易所 交 易 系 统 进 行 网 络 投 票 的 时 间 为 2025 年 10 月 9 日 9:15-9:25 、 ...

深圳市美好创亿医疗科技股份有限公司监事会 关于 2025 年限制性股票激励计划预留授予激励对象名单 （第一批次）的核查意见 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）监事会依据《公 司法》《证券法》《上市公司股权激励管理办法》《深圳证券交易所创业板股票上 市规则》《深圳证券交易所创业板上市公司自律监管指南第 1 号—业务办理》《公 司章程》等有关规定，对 2025 年限制性股票激励计划（以下简称"本激励计划"） 预留授予激励对象名单（第一批次）进行核查，发表核查意见如下： 一、激励对象符合《公司法》《证券法》《公司章程》规定的任职资格；符合 《深圳证券交易所创业板股票上市规则》规定的激励对象条件，包括：1、不存 在最近 12 个月内被证券交易所认定为不适当人选的情形；2、不存在最近 12 个 月内被中国证监会及其派出机构认定为不适当人选的情形；3、不存在最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政处罚或者采取市场 禁入措施的情形；4、不存在具有《公司法》规定的不得担任公司董事、高级管 理人员情形的情形；5、不存在具有法律法规规定不得参与上市公司股权激励的 情形；6、不存在中国证 ...

证券代码：301363 证券简称：美好医疗 公告编号：2025-059 深圳市美好创亿医疗科技股份有限公司 第二届监事会第十八次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）第二届监事会 第十八次会议通知于2025年9月5日以书面、电话等方式送达全体监事，并于2025 年9月15日在公司会议室召开现场会议。本次会议由监事会主席黎莎女士主持， 会议应到监事3人，实到监事3人，会议的召集和召开符合《中华人民共和国公司 法》《公司章程》等相关规定。 二、监事会会议审议情况 经全体与会监事认真审议、充分讨论，会议审议并通过了以下议案： （一）审议通过《关于变更注册资本、变更经营范围并修订<公司章程>的 议案》 经审议，监事会认为：公司本次变更注册资本、变更经营范围并修订《公司 章程》，符合《上市公司章程指引》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》《关于 新<公司法>配套制度规则实施相关过渡期安排》等相关法律 ...

证券代码：301363 证券简称：美好医疗 公告编号：2025-058 深圳市美好创亿医疗科技股份有限公司 第二届董事会第二十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）第二届董事会 第二十一次会议通知于2025年9月5日以书面、电话等方式送达全体董事，并于 2025年9月15日在公司会议室以现场结合通讯方式召开。本次会议由董事长熊小 川先生主持，会议应到董事9人，实际参会董事9人，其中独立董事吴学斌、独立 董事梁永晔、独立董事王建新、董事Florian Then、董事Joel Chan、董事孙超 以通讯方式参会。经全体与会董事确认，本次会议的召集、召开以及审议程序符 合《中华人民共和国公司法》《公司章程》和《董事会议事规则》等有关规定， 会议形成的决议合法、有效。 二、董事会会议审议情况 经全体与会董事认真审议、充分讨论，会议审议并通过了以下议案： （一）审议通过《关于变更注册资本、变更经营范围并修订<公司章程>的 议案》 公司2024年年度权益分派方案已于2 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of September 15, 2025 [1] Core Insights - The trend of Chinese innovative drugs going overseas continues, with a focus on selective opportunities. The report highlights that the global pharmaceutical transaction volume reached 456 deals in the first half of 2025, a 32% year-on-year increase, with upfront payments totaling $11.8 billion, a 136% surge, and total transaction value hitting $130.4 billion, up 58% year-on-year [2] - The report emphasizes the promising clinical data from Chinese innovative drugs presented at the World Lung Cancer Conference, particularly in the ADC (Antibody-Drug Conjugate) field, showcasing significant efficacy advantages [3] - The report discusses the potential of small nucleic acid drugs and innovative delivery systems, indicating new market opportunities arising from strategic collaborations between Chinese companies and multinational corporations [4] - The CXO (Contract Research Organization) sector is expected to gradually recover, with a notable increase in orders anticipated in the third quarter of 2025, driven by improved innovation environments and funding from license-out transactions [5] - The 2025 medical insurance negotiation and commercial insurance innovative drug directory work has commenced, with a focus on orphan drugs and breakthrough treatment varieties [6] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry underperformed the CSI 300 index by 1.75% in the past week, with a recent one-month increase of 3.32%, lagging behind the CSI 300 by 5.81% [22][26] - The medical device sector showed the highest weekly increase of 2.23%, while the chemical pharmaceutical sector experienced a decline of 2.57% [31] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index's current PE (TTM) stands at 40.60, above the five-year historical average of 31.60 [46] - The report notes that the pharmaceutical sector has shown a 15.06% increase over the past three months, outperforming the CSI 300 by 16.11% [43] 3. Recent Research Achievements - The report outlines recent research achievements by the Huaxin pharmaceutical team, including various in-depth and commentary reports on innovative drug developments and market trends [50] 4. Recent Industry Policies and News - The report details recent policy updates from the National Healthcare Security Administration regarding the 2025 drug directory adjustments and the approval of new drug applications [52][55]

Core Insights - The International Medical Aesthetic Anti-Aging Conference (IMCAS) was successfully held in Shanghai from July 11 to 13, 2025, attracting nearly 200 global experts and thousands of industry professionals to discuss cutting-edge topics in plastic surgery and injectable aesthetics [1][2] - Dr. Xue Zhiqiang, a leading figure in the aesthetic field, presented innovative clinical techniques from China, emphasizing the importance of precise treatment strategies for complications arising from injectable materials [2][3] Group 1: Conference Highlights - IMCAS serves as a significant academic platform for global medical aesthetics professionals, promoting collaboration and innovation in treatment technologies [1] - The conference featured in-depth discussions on the rising incidence of complications from injectable aesthetics, particularly issues related to hyaluronic acid and collagen stimulators [3] Group 2: Dr. Xue Zhiqiang's Contributions - Dr. Xue introduced a tiered treatment strategy for complications caused by collagen stimulators, advocating for ultrasound-guided injections to precisely target problem areas [3] - His presentations highlighted the effectiveness of plasma radiofrequency ablation as a minimally invasive solution for stubborn nodules and granulomas, particularly in sensitive facial regions [3] Group 3: Industry Recognition and Achievements - According to a report by Sullivan, JunTai Medical ranked first in the number of patients treated with ultrasound-assisted repair techniques in 2024, showcasing its clinical strength and industry recognition [4] - Dr. Xue's expertise in the application of collagen stimulators has positioned him as a leading figure in the field, with his techniques being widely acknowledged by peers [6][7] Group 4: Educational Initiatives - JunTai Medical has actively promoted the ultrasound-guided repair technique through training programs, successfully conducting over 40 industry training sessions to share core operational experiences [9][10] - The company's commitment to open and shared academic practices aims to elevate the overall technical standards within the medical aesthetics industry [10] Group 5: Future Directions - JunTai Medical continues to focus on high-quality, personalized aesthetic services, integrating digital diagnosis and evidence-based medicine to enhance patient outcomes [12][13] - The company emphasizes the importance of adhering to industry standards and maintaining a patient-centered approach in its operations [13]

Group 1 - The company, Su Lian Co., announced the election of Mr. Han Zongjun as the chairman [2]

Core Viewpoint - The stock of Meihao Medical (301363) has experienced a decline, with a closing price of 26.06 yuan on September 12, 2025, down by 1.88% [1] Group 1: Stock Performance and Trading Data - On September 12, 2025, the stock had a turnover rate of 6.82%, with a trading volume of 106,500 hands and a transaction amount of 278 million yuan [1] - The net inflow of main funds was 31.17 million yuan, accounting for 7.33% of the total transaction amount, while retail investors saw a net outflow of 10.76 million yuan, representing 2.53% of the total [1] - Over the past five days, the stock has shown fluctuating performance, with a notable increase in main fund inflow on September 10, 2025, amounting to 33.34 million yuan, which was a 6.98% increase in stock price [2] Group 2: Financial Metrics and Industry Comparison - Meihao Medical's total market value is 14.995 billion yuan, with a net asset of 3.595 billion yuan and a net profit of 114 million yuan, ranking 23rd, 42nd, and 40th respectively in the medical device industry [3] - The company's revenue for the first half of 2025 was 733 million yuan, a year-on-year increase of 3.73%, while the net profit decreased by 32.44% to 114 million yuan [3] - The gross profit margin stands at 37.52%, significantly lower than the industry average of 51.85%, indicating potential challenges in profitability [3] Group 3: Analyst Ratings and Market Sentiment - In the last 90 days, 17 institutions have rated the stock, with 15 buy ratings and 2 hold ratings, suggesting a generally positive outlook among analysts [4] - The average target price set by institutions over the past 90 days is 26.48 yuan, indicating a slight upside potential from the current trading price [4]

Market Overview - On September 10, the medical device sector declined by 0.6%, with Zhongke Meiling leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Top Gainers in Medical Device Sector - Meihua Medical (301363) closed at 26.50, up 6.98% with a trading volume of 232,100 shares and a turnover of 601 million yuan [1] - Kangwei Century (688426) closed at 29.46, up 6.74% with a trading volume of 57,600 shares and a turnover of 171 million yuan [1] - Mailande (688273) closed at 41.19, up 5.13% with a trading volume of 27,500 shares and a turnover of 112 million yuan [1] Top Losers in Medical Device Sector - Zhongke Meiying (835892) closed at 23.04, down 7.80% with a trading volume of 55,400 shares and a turnover of 130 million yuan [2] - AoJing Medical (688613) closed at 25.42, down 4.40% with a trading volume of 134,700 shares and a turnover of 341 million yuan [2] - Kangzhong Medical (688607) closed at 29.18, down 3.35% with a trading volume of 25,700 shares and a turnover of 75.5 million yuan [2] Capital Flow Analysis - The medical device sector experienced a net outflow of 638 million yuan from institutional investors, while retail investors saw a net inflow of 580 million yuan [2][3] - Major stocks like Meihua Medical had a net inflow of 33.34 million yuan from institutional investors, while retail investors had a net outflow of 12.26 million yuan [3] Summary of Individual Stock Performance - Meihua Medical (301363) had a net inflow of 33.34 million yuan from major investors, but a net outflow of 12.26 million yuan from retail investors [3] - ZhenDe Medical (603301) saw a net inflow of 25.49 million yuan from major investors, while retail investors experienced a net outflow of 34.90 million yuan [3] - Kangwei Century (688426) had a net inflow of 13.83 million yuan from major investors, with a significant net outflow from retail investors [3]

Group 1 - The core viewpoint of the news is the performance and financial details of Shenzhen Meihao Medical Technology Co., Ltd., which saw a stock price increase of 5.89% to 26.23 CNY per share, with a total market capitalization of 14.921 billion CNY [1] - The company was established on July 15, 2010, and went public on October 12, 2022, focusing on the design, development, manufacturing, and sales of medical device components and products [1] - The revenue composition of the company includes: home respiratory machine components (59.48%), home and consumer electronics components (14.61%), other medical product components (10.33%), cochlear implant components (8.16%), precision molds and automation equipment (5.63%), other categories (1.09%), and proprietary products (0.70%) [1] Group 2 - From the perspective of fund holdings, Meihao Medical is a significant investment for the China Europe Fund, specifically in the China Europe Jiaxuan Mixed A Fund (010947), which held 823,900 shares, accounting for 1.53% of the fund's net value [2] - The fund has achieved a year-to-date return of 27.32% and a one-year return of 58.99%, ranking 2505 out of 8177 and 1917 out of 7982 respectively in its category [2] - The fund manager, Wang Jian, has a tenure of 15 years and 322 days, with the fund's total asset size at 6.565 billion CNY and a best return of 200.87% during his management [3]